# A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

> **NCT00963807** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage IB Non-Small Cell Lung Carcinoma
- Stage IIA Non-Small Cell Lung Carcinoma
- Stage IIB Non-Small Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **PROCEDURE:** CT
- **DRUG:** Docetaxel
- **DRUG:** FDG
- **DRUG:** FLT
- **PROCEDURE:** PET/CT
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT00963807
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-08
- **Final completion:** 2014-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963807, "A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00963807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*